Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Omaha, NE
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Henderson, NV
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Albany, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Binghamton, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Binghamton, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Bronx, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Hudson, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Hudson, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Johnson City, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Johnson City, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New York, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Charleston, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Easley, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Easley, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Greenville, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Greer, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Sumter, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Sumter, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Arlington, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
El Paso, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Houston, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Paris, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Paris, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Plano, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Tyler, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
American Fork, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
American Fork, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Bountiful, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Bountiful, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Murray, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Provo, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Provo, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
West Jordan, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Roanoke, VA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Vancouver, WA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
mi
from
Bentleigh East,
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
mi
from
Bentleigh East,
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Birmingham, AL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chandler, AZ
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Sedona, AZ
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Sedona, AZ
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
La Jolla, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Oxnard, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
San Diego, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
San Francisco, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Santa Monica, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Aurora, CO
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Denver, CO
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Washington,
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Hialeah, FL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Miami, FL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials